Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies
Sponsor: Shanghai Jiao Tong University School of Medicine
Summary
In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.
Official title: A Multiple-center Phase II Study to Evaluate the Clinical Outcome of Reduced Conditioning Regimen With Melphalan, Busulfan and Fludarabine for Patients >=55 Years With Myeloid Malignancies.
Key Details
Gender
All
Age Range
55 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
61
Start Date
2022-06-01
Completion Date
2027-06-30
Last Updated
2026-03-17
Healthy Volunteers
No
Conditions
Interventions
MBF-RIC
Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan
Locations (2)
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, Shanghai Municipality, China
Shanghai No 6 Hospital
Shanghai, China